Latest Headlines

  1. Aureka Releases OpenDDE, An Open-Source Drug Discovery Engine Designed To Accelerate AI-Driven Therapeutic Discovery 7/6/2026

    Aureka, an AI TechBio company building infrastructure for AI-driven biologics discovery, today announced the release of Open Drug Discovery Engine (OpenDDE), an open-source, all-atom biomolecular foundation model designed to serve as the structural reasoning core of next-generation drug discovery systems.

  2. Ascletis Submits Two IND Applications To The U.S. FDA For The Treatment Of Obesity: ASC36 Once-Monthly Injection, A Peptide Amylin Receptor Agonist, And ASC36_35 FDC Once-Monthly Injection, A Co-Formulation Of ASC36 Plus Peptide GLP-1R/GIPR Agonist ASC35 7/5/2026

    Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today recent submissions of two Investigational New Drug (IND) applications to the U.S. Food and Drug Administration (FDA) for ASC36, a once-monthly to once-quarterly next-generation peptide amylin receptor agonist and ASC36_35 FDC, a once-monthly injection co-formulation of ASC36 plus peptide GLP-1R/GIPR agonist ASC35, for the treatment of obesity.

  3. INTENT Biologics Receives FDA Breakthrough Therapy Designation For PEP Biologic For Its Phase 3 Ready Flagship Indication 7/1/2026

    INTENT Biologics, a clinical-stage biotechnology company developing first-in-class exosome-based biologic therapies for serious conditions with significant unmet medical need, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for PEP Biologic for the treatment of diabetic foot ulcers (DFU) under IND 019567.

  4. NorthStrive Biosciences Announces Positive Results From Phase III Of AI-Driven Drug Discovery Program With Yuva Biosciences 7/1/2026

    NorthStrive Biosciences Inc. ("NorthStrive Biosciences"), a subsidiary of PMGC Holdings Inc. (NASDAQ: ELAB) ("PMGC" or the "Company"), today announced positive results from Phase III of its AI-driven drug discovery program with strategic partner Yuva Biosciences, Inc. ("Yuva Biosciences").

  5. Insilico Medicine Announces Collaboration With Takeda To Advance Strategic AI Drug Discovery 7/1/2026

    Insilico Medicine ("Insilico" HKEX:3696), a leader in clinical-stage generative AI for drug discovery, today announced a strategic collaboration agreement with Takeda to use its proprietary end-to-end platform, Pharma.AI, to advance drug candidates across the company's therapeutic areas.

  6. Lonza Expands HPAPI Capacity In Visp, Further Supporting Its Position In Payload-Linker Manufacturing 6/30/2026
  7. Altasciences Supports Key Development Milestone For Steel Therapeutics' Lead Therapeutic Candidate, Fizurex 6/30/2026

    Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex, for the treatment of anal fissures.

  8. Tsingke Biotech Hosts Shanghai Salon On Oligonucleotide Drugs, Spotlighting Next-Gen RNA Therapeutics 6/30/2026

    Tsingke Biotech recently hosted the Oligonucleotide Drug Salon at the Hilton Shanghai Zhangjiang, bringing together experts from academia, biopharmaceutical companies, investment firms, and industry service organizations to discuss technological innovation, CMC development, delivery technologies, regulatory strategies, and commercialization pathways in the rapidly evolving field of oligonucleotide therapeutics.

  9. Inductive Bio Joins Anthropic's Connector Ecosystem For Life Sciences, Surfacing State-Of-The-Art ADMET Prediction To Drug Discovery Scientists Through Claude 6/30/2026

    Inductive Bio, an AI drug discovery partner developing virtual chemistry labs, today announced that it has joined Anthropic's life sciences ecosystem and launched a Model Context Protocol (MCP) connector that makes its ADMET (Absorption, Distribution, Metabolism, Excretion, & Toxicity) prediction models accessible directly within Claude.

  10. Enhertu Approved In The EU As First Tumor Agnostic HER2 Directed Therapy And Antibody Drug Conjugate For Patients With Previously Treated HER2 Positive Metastatic Solid Tumors 6/29/2026

    Enhertu (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options.